In this review:
- LIBRETTO-432: adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC
- HARMONi-6: chemotherapy + ivonescimab vs. tislelizumab in squamous NSCLC
- CROWN: lorlatinib vs. crizotinib in ALK+ NSCLC
- WU-KONG28: sunvozertinib vs. chemotherapy in NSCLC with EGFR exon20ins
- OptiTROP-Lung05: sacituzumab tirumotecan ± pembrolizumab in PD-L1+ NSCLC
- FLAME: osimertinib ± chemotherapy in persistent ctDNA EGFR-altered NSCLC after osimertinib monotherapy
- LORIN: neoadjuvant lorlatinib in stage 3 ALK-fusion NSCLC
- TRITON: tremelimumab + durvalumab + chemotherapy vs. pembrolizumab + chemotherapy in STK11/KEAP1/KRAS-altered NSCLC
- ALCHEMIST EA5142: adjuvant nivolumab after standard adjuvant therapy in resected NSCLC
- NIBIT-EPI-MESO: tumour methylation subtypes in pleural mesothelioma
Please login below to download this issue (PDF)